中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (1): 79-83.doi: 10.12144/zgmfskin202501079

• 综述 • 上一篇    下一篇

超说明书应用阿普米司特治疗皮肤病进展

李慧杰1,2，焦雨竹1,2，杨青1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022; 2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2025-01-15 发布日期:2024-12-24

Off-label uses of apremilast in dermatology

LI Huijie1,2, JIAO Yuzhu1,2, YANG Qing1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2025-01-15 Published:2024-12-24

PDF (PC)

126

摘要： 阿普米司特是一种通过抑制磷酸二酯酶-4（PDE4）发挥作用的小分子药物，已在我国获批治疗斑块状银屑病。笔者以“apremilast”为关键词对PubMed数据库进行检索，并对银屑病关节炎、白塞病、白癜风、斑秃、化脓性汗腺炎和特应性皮炎的随机对照试验数据，以及该药应用于特应性皮炎、Hailey-Hailey病、化脓性汗腺炎、皮肌炎、系统性硬化症、慢性光化性皮炎及坏疽性脓皮病等疾病的病例报道进行了综述，为该药在皮肤科的应用提供借鉴。

关键词: 阿普米司特, 皮肤疾病, 超说明书应用

Abstract: Apremilast, a small molecule that acts by inhibition of the phosphodiesterase-4 enzyme, has been approved for the management of plaque psoriasis in China. Utilizing‘apremilast’ as a keyword in the title, the PubMed database was searched for randomized controlled trial data on psoriatic arthritis, Behet's disease, vitiligo, alopecia and hidramatitis, and case reports of atopic dermatitis, Hailey-Hailey disease, hidradenitis suppurativata, dermatomyositis, systemic sclerosis, chronic actinic dermatitis and pyoderma gangrenosum treated with apremilast. Then we summarized the retrieved literature offering a reference for clinical practice.

Key words: apremilast, dermatosis, off-label use